Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

beta-Thalassemia × luspatercept × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Myeloproliferative Disorders 4 Myelodysplastic Syndromes 4 Primary Myelofibrosis 2 Leukemia, Myeloid, Acute 2 Anemia 2 beta-Thalassemia 1 Higher-risk Myelodysplastic Syndrome 1

Interventions

thymoglobulin 2 fludarabine 2 Rituximab 2 Cyclophosphamide 2 luspatercept 1 Tacrolimus 1 Mycophenolic Acid 1 Melphalan 1 Levetiracetam 1 Dexamethasone 1 Busulfan 1 Bortezomib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04064060 2025-11-12

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Celgene

Phase 3 Recruiting

Myelodysplastic Syndromes, Myeloproliferative Disorders, beta-Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡